ANALYSING THE VOLUME OF DRUG CONSUMPTION IN INPATIENT TREATMENT OF EPILEPSY

The article presents the results of the study of the volume of consumption of medicinal drugs for the treatment of patients diagnosed with epilepsy. As a result of retrospective processing of case histories (continuous sampling for 2021-2023) obtained in the inpatient department of the Clinic of Nervous Diseases named after A.Y. Khlebnikov of Sechenov University, the dynamics of drugs consumption from 2021 to 2023 was analyzed. The range of antiepileptic drugs in the clinic in 2022-2023 compared to 2021 was supplemented with such names as: topiramate, oxcarbazepine. Increased consumption of levetiracetam in 2023 compared to 2021 by 4 times. Based on the data obtained, it is obvious that there are no 3rd generation antiepileptic drugs in the assortment. Among other pharmacotherapeutic groups the leading position is occupied by B vitamins, the volume of consumption of these drugs in 2023 amounted to 496.86 NDDD/100 bed days. In addition, a decrease in the consumption of myorelaxants should be noted. The results obtained can be the basis for the development of recommendations to optimize the use of drugs and improve the quality of drug care for patients with epilepsy at the inpatient level.